Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. OABI
OABI logo

OABI Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy OmniAb Inc (OABI) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Hold
Latest Price
1.650
1 Day change
-0.60%
52 Week Range
2.290
Analysis Updated At
2026/04/24
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.
Sign Up

OmniAb Inc (OABI) is not a good buy for a beginner, long-term investor at this time. The stock shows weak financial performance, no significant positive catalysts, and a high likelihood of short-term price decline based on technical and trend analysis. Additionally, there are no strong trading signals or favorable sentiment indicators to support a buy decision.

Technical Analysis

The MACD histogram is positive at 0.0126 and expanding, suggesting a mild bullish momentum. RSI is neutral at 55.602, and moving averages are converging, indicating no clear trend. Key support and resistance levels are Pivot: 1.532, R1: 1.616, S1: 1.448. However, the stock has a 90% chance of declining by -0.69% in the next day, -2.26% in the next week, and -6.4% in the next month.

Options Data

Bullish
Open Interest Put-Call Ratio
Bullish
Option Volume Put-Call Ratio

Technical Summary

StrongSellSellNeutralBuyStrongBuydotted line Image
Sell
7
Buy
6

Positive Catalysts

  • NULL identified. No recent news or significant insider or hedge fund activity.

Neutral/Negative Catalysts

  • Weak financial performance in Q3 2025, with revenue dropping by -46.33% YoY, EPS declining by -12.50% YoY, and gross margin deteriorating significantly to -45.47%. Additionally, there is no recent congress trading data or influential figures showing interest in the stock.

Financial Performance

In Q3 2025, revenue dropped to $2.239 million (-46.33% YoY), net income slightly improved to -$16.525 million (+0.93% YoY), EPS dropped to -0.14 (-12.50% YoY), and gross margin fell sharply to -45.47% (-145.47% YoY). Overall, the company's financials indicate declining performance.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No recent analyst ratings or price target changes available for OABI.

Wall Street analysts forecast OABI stock price to rise
6 Analyst Rating
Wall Street analysts forecast OABI stock price to rise
6 Buy
0 Hold
0 Sell
Strong Buy
Current: 1.660
sliders
Low
3
Averages
6.8
High
11
Current: 1.660
sliders
Low
3
Averages
6.8
High
11
Craig-Hallum
Buy
downgrade
$10 -> $7
AI Analysis
2025-11-05
Reason
Craig-Hallum
Price Target
$10 -> $7
AI Analysis
2025-11-05
downgrade
Buy
Reason
Craig-Hallum lowered the firm's price target on OmniAb to $7 from $10 and keeps a Buy rating on the shares. The firm notes the company reported several positive developments this quarter, driven by strong business momentum and a growing network of 104 active partners. Additionally, Craig-Hallum believes that the launch of OmniUltra, following last quarter's introduction of the xPloration Partner Access Program, should facilitate the development of new classes of biologically derived peptide therapeutics and this innovation will drive further partnerships.

People Also Watch